title: [Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
abstract: Basic and pre-clinic research in cellular and molecular oncology are the main supports accounting for the advancement in cancer therapeutics. The findings achieved, and their implementation in clinical practice are responsible for the permanent improvement in the treatment of the neoplastic disease. Our present objective is to summarize and discuss the pre-clinical findings in immunomodulation and anti-angiogenesis for the treatment of several types of tumors obtained in our Institute during the last 15 years, and the subsequent translation and application of the acquired experimental knowledge in a Phase I/II Clinical Trial. We present the results and mechanisms of action of antimetastatic immunomodulation with cyclophosphamide, the metronomic chemotherapy with different single drugs and their combinations, and finally the design and preliminary results of a clinical trial with metronomic chemotherapy for patients with advanced breast cancer.
authors.affiliation: Instituto de Genética Experimental, Facultad de Ciencias Médicas, Universidad Nacional de Rosario. graciela.scharovsky@gmail.com
authors.forename: O Graciela
authors.initials: OG
authors.lastname: Scharovsky
authors.forename: Pablo
authors.initials: P
authors.lastname: Matar
authors.forename: Viviana R
authors.initials: VR
authors.lastname: Rozados
authors.forename: María J
authors.initials: MJ
authors.lastname: Rico
authors.forename: Mariano F
authors.initials: MF
authors.lastname: Zacarías Fluck
authors.forename: Leandro E
authors.initials: LE
authors.lastname: Mainetti
authors.forename: M Virginia
authors.initials: MV
authors.lastname: Fernández Zenóbi
authors.forename: Eduardo A
authors.initials: EA
authors.lastname: Roggero
authors.forename: Silvia I
authors.initials: SI
authors.lastname: Gervasoni
authors.forename: Ana
authors.initials: A
authors.lastname: Rossa
authors.forename: Hernán A
authors.initials: HA
authors.lastname: Perroud
authors.forename: Andrea M
authors.initials: AM
authors.lastname: Sánchez
authors.forename: Guillermo C
authors.initials: GC
authors.lastname: Celoria
authors.forename: María T
authors.initials: MT
authors.lastname: Font
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D056747:Immunomodulation; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000098:blood supply / Q000276:immunology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D011720:Pyrazoles / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D018906:Antineoplastic Agents, Alkylating; D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D003520:Cyclophosphamide; D000068579:Celecoxib